(19)
(11)EP 3 679 025 B8

(12)CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15)Correction information:
Corrected version no 1 (W1 B1)

(48)Corrigendum issued on:
15.06.2022 Bulletin 2022/24

(45)Mention of the grant of the patent:
04.05.2022 Bulletin 2022/18

(21)Application number: 18769603.4

(22)Date of filing:  31.08.2018
(51)International Patent Classification (IPC): 
C07D 401/04(2006.01)
A61P 35/00(2006.01)
A61K 31/437(2006.01)
(52)Cooperative Patent Classification (CPC):
A61K 31/437; C07D 401/04; A61P 35/00
(86)International application number:
PCT/EP2018/073485
(87)International publication number:
WO 2019/048353 (14.03.2019 Gazette  2019/11)

(54)

SUBSTITUTED IMIDAZOQUINOLINES AS AGONISTS OF TLR7

SUBSTITUIERTE IMIDAZOCHINOLINE ALS TLR7-AGONISTEN

IMIDAZOQUINOLINES SUBSTITUÉES UTILISÉES EN TANT QU'AGONISTES DE TLR7


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30)Priority: 06.09.2017 WO PCT/EP2017/072353

(43)Date of publication of application:
15.07.2020 Bulletin 2020/29

(60)Divisional application:
22169256.9

(73)Proprietor: BioNTech SE
55131 Mainz (DE)

(72)Inventor:
  • HENRY, Christophe
    81479 Munich (DE)

(74)Representative: Müller, Christian Stefan Gerd 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)


(56)References cited: : 
WO-A2-2005/051324
US-B1- 6 573 273
WO-A2-2009/118296
  
      
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).